Suppr超能文献

κ-阿片受体激动剂盐酸(-)-17-环丙甲基-3,14β-二羟基-4,5α-环氧-β-[N-甲基-3-反式-3-(3-呋喃基)丙烯酰胺基]吗啡喃(TRK-820)对小鼠急性疱疹性疼痛相关反应的抑制作用

Suppression of acute herpetic pain-related responses by the kappa-opioid receptor agonist (-)-17-cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-beta-[n-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) in mice.

作者信息

Takasaki Ichiro, Suzuki Tomohiko, Sasaki Atsushi, Nakao Kaoru, Hirakata Mikito, Okano Kiyoshi, Tanaka Toshiaki, Nagase Hiroshi, Shiraki Kimiyasu, Nojima Hiroshi, Kuraishi Yasushi

机构信息

Department of Applied Pharmacology, Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan.

出版信息

J Pharmacol Exp Ther. 2004 Apr;309(1):36-41. doi: 10.1124/jpet.103.059816. Epub 2004 Jan 7.

Abstract

(-)-17-Cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6beta-[N-methyl-3-trans-3-(3-furyl) acrylamido] morphinan hydrochloride (TRK-820) is a kappa-opioid receptor agonist that has pharmacological characteristics different from typical kappa-opioid receptor agonists. This study was conducted to determine the antiallodynic and antihyperalgesic effects of TRK-820 in a mouse model of acute herpetic pain and to compare them with those of the kappa-opioid receptor agonist enadoline and the mu-opioid receptor agonist morphine. Percutaneous inoculation with herpes simplex virus type-1 induced tactile allodynia and mechanical hyperalgesia in the hind paw on the inoculated side. TRK-820 (0.01-0.1 mg/kg p.o.), enadoline (1-10 mg/kg p.o.) and morphine (5-20 mg/kg p.o.) dose dependently inhibited the allodynia and hyperalgesia, but the antiallodynic and antihyperalgesic dose of enadoline markedly decreased spontaneous locomotor activity. The antinociceptive action of TRK-820 (0.1 mg/kg) was completely antagonized by pretreatment with norbinaltorphimine, a kappa-opioid receptor antagonist, but not by naltrexone, a mu-opioid receptor antagonist. Repeated treatment with morphine (20 mg/kg, four times) resulted in the reduction of antiallodynic and antihyperalgesic effects, whereas the inhibitory potency of TRK-820 (0.1 mg/kg) was almost the same even after the fourth administration. There was no cross-tolerance in antinociceptive activities between TRK-820 and morphine. Intrathecal and intracerebroventricular, but not intraplantar, injections of TRK-820 (10-100 ng/site) suppressed the allodynia and hyperalgesia. These results suggest that TRK-820 inhibits acute herpetic pain through kappa-opioid receptors in the spinal and supraspinal levels. TRK-820 may have clinical efficacy in acute herpetic pain with enough safety margins.

摘要

(-)-17-环丙基甲基-3,14β-二羟基-4,5α-环氧-6β-[N-甲基-3-反式-3-(3-呋喃基)丙烯酰胺基]吗啡喃盐酸盐(TRK-820)是一种κ-阿片受体激动剂,具有与典型κ-阿片受体激动剂不同的药理学特性。本研究旨在确定TRK-820在急性疱疹性疼痛小鼠模型中的抗痛觉过敏和抗痛觉超敏作用,并将其与κ-阿片受体激动剂依那朵林和μ-阿片受体激动剂吗啡的作用进行比较。经皮接种1型单纯疱疹病毒可诱导接种侧后爪出现触觉痛觉过敏和机械性痛觉超敏。TRK-820(0.01-0.1毫克/千克,口服)、依那朵林(1-10毫克/千克,口服)和吗啡(5-20毫克/千克,口服)剂量依赖性地抑制痛觉过敏和痛觉超敏,但依那朵林的抗痛觉过敏和抗痛觉超敏剂量显著降低自发运动活性。TRK-820(0.1毫克/千克)的抗伤害感受作用被κ-阿片受体拮抗剂 norbinaltorphimine预处理完全拮抗,但未被μ-阿片受体拮抗剂纳曲酮拮抗。吗啡(20毫克/千克,四次)重复给药导致抗痛觉过敏和抗痛觉超敏作用减弱,而TRK-820(0.1毫克/千克)即使在第四次给药后抑制效力仍几乎相同。TRK-820和吗啡之间在抗伤害感受活性方面不存在交叉耐受性。鞘内和脑室内注射TRK-820(10-100纳克/部位)可抑制痛觉过敏和痛觉超敏,但足底注射则无此作用。这些结果表明,TRK-820通过脊髓和脊髓上水平的κ-阿片受体抑制急性疱疹性疼痛。TRK-820在急性疱疹性疼痛中可能具有临床疗效且有足够的安全范围。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验